Revumenib
Revumenib (SNDX-5613) is a potent and specific Menin-MLL inhibitor with a binding Ki of 0.149 nM and a cell based IC50 of 10-20 nM. Revumenib can be used for the research of MLL-rearranged (MLL-r) acute leukemias, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) [1].
Product Specifications
CAS Number
[2169919-21-3]
Product Name Alternative
SNDX-5613
UNSPSC
12352005
Hazard Statement
H302, H315, H319
Target
Epigenetic Reader Domain
Type
Reference compound
Related Pathways
Epigenetics
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/revumenib.html
Purity
99.99
Solubility
DMSO : ≥ 25 mg/mL
Smiles
O=C(N(CC)C(C)C)C1=CC(F)=CC=C1OC2=CN=CN=C2N3CC4(CCN(C[C@H]5CC[C@H](NS(=O)(CC)=O)CC5)CC4)C3
Molecular Formula
C32H47FN6O4S
Molecular Weight
630.82
Precautions
H302, H315, H319
References & Citations
[1]A drug, SNDX-5613, to treat acute leukemia with a KMT2A translocation or an NPM1 mutation that has come back (relapsed) or has not gotten better with treatment (refractory) .
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Available Sizes
More Discoveries
Explore Other Products
Browse additional items from our catalog
